Bioseet interview with Delta4 CEO, Kurt Herpel

Delta4 is a Swiss-Austrian digital drug discovery and development company for rare diseases. Delta4 focuses on discovering undetected relationships between drugs with a known safety profile and diseases to identify new indications, by utilizing Hyper-C, an artificial intelligence powered platform that allows to detect these relationships with unprecedented speed.